Scarica l'app Stockscreener
5.30
6.11%
0.305
Dopo l'orario di chiusura:
5.28
-0.02
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SELLAS Life Sciences Group Inc (SLS) Stock News & Articles - 24/7 Wall St.
SLS Eyes New Capital Streams with Securities Shelf Registration - StocksToTrade
Sellas Life Sciences: New Price Targets Signal Optimism Amid Clinical Progress - StocksToTrade
SLS Technical Analysis | Trend, Signals & Chart Patterns | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS Life Sciences Group, Inc.(NasdaqCM:SLS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Penny Stocks To ResearchMarch 22nd - MarketBeat
Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run - Yahoo Finance
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
Penny Stocks To Watch NowMarch 21st - MarketBeat
BUY Rating on SELLAS: Pivotal REGAL Phase 3 Progress, Expanding AML Pipeline, and Cash Runway into 2027 Support Upside Potential - TipRanks
Investment Review: Whats the beta of SELLAS Life Sciences Group Inc stockMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
SELLAS Life Sciences Group, Inc.: Fundamental Analysis and Financial Ratings | | US81642T2096 - marketscreener.com
SELLAS Life Sciences’ AML Pipeline Adds Key Clinical Checkpoints For Investors - simplywall.st
Form S-3ASR Sellas Life Sciences Group Inc For: 20 March - Investing.com
SELLAS (NASDAQ: SLS) registers shelf and $150M ATM with TD Cowen - Stock Titan
SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates - Stocktwits
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths - 24/7 Wall St.
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences 2025 net loss narrows, cash position strengthens - TradingView
SLS: Strong cash position and clinical progress in AML set stage for pivotal 2026 - TradingView
[8-K] SELLAS Life Sciences Group, Inc. Report... - Stock Titan
BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million - TradingView
SELLAS Life Sciences 2025 10-K: Revenue $0.0M, EPS $(0.25) - TradingView
SELLAS nears key leukemia trial readout after raising $42.6M in Q1 - Stock Titan
[10-K] SELLAS Life Sciences Group, Inc. Files Annual Report | SLS SEC FilingForm 10-K - Stock Titan
SLS: Net loss improved to $26.9M in 2025; strong cash reserves support ongoing clinical programs - TradingView
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Investment Recap: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Market WrapUp & Daily Growth Stock Tips - baoquankhu1.vn
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
Sellas to present preclinical data on SLS009 at cancer conference By Investing.com - Investing.com India
SELLAS Life Sciences: SLS009’s Two-Pronged AML Clinical Approach Evaluates CDK9’s Leading Role Ahead of a Key Q4 2026 Milestone - Bitget
Sellas Life Sciences to present preclinical SLS009 data at AACR conference - TipRanks
Sellas to present preclinical data on SLS009 at cancer conference - Investing.com
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference - Bitget
Can SELLAS Life Sciences Group Inc beat the S P 500Weekly Risk Summary & Consistent Growth Equity Picks - baoquankhu1.vn
SLS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds - Investing.com Nigeria
Sellas Life Sciences Group Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Anson Funds Management LP Has $9.71 Million Position in SELLAS Life Sciences Group, Inc. $SLS - MarketBeat
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 - Investing.com Nigeria
A Look At SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Gains - simplywall.st
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% HigherWhat's Next? - MarketBeat
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 By Investing.com - Investing.com South Africa
SLS stock in spotlight: First AML patient enrolled in phase 2 leukemia trial - MSN
Sellas Says First Patient Enrolled in Phase 2 Trial of SLS009 in Acute Myeloid Leukemia - marketscreener.com
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial - Asianet Newsable
According to the latest merger agreement terms, Signature Bank shareholders will receive an equity allocation at a ratio of 2.63 shares of Esquire Financial Holdings Inc. for each share of Signature stock. - Bitget
Major Bank Ratings | Evercore ISI: Raises Ryanair target price to $80, rating upgraded to "Outperform" - Bitget
Sellas announces enrollment of first patient in Phase 2 SLS009 trial - TipRanks
SELLAS Life Sciences Group Inc. announced that the first patient has been enrolled in the clinical trial of its innovative drug SLS009 for first-line treatment of newly diagnosed acute myeloid leukemia (AML). - Bitget
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):